Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment: the decision to establish a ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...